Shimada, Kazuyuki http://orcid.org/0000-0002-1075-9219
Ohmachi, Ken
Machida, Ryunosuke
Ota, Shuichi
Itamura, Hidekazu
Tsujimura, Hideki
Takayama, Nobuyuki
Shimada, Takaki
Kurosawa, Mitsutoshi
Tabayashi, Takayuki
Shimoyama, Tatsu
Ohshima, Koichi
Miyazaki, Kana
Maruyama, Dai
Kinoshita, Tomohiro
Ando, Kiyoshi
Hotta, Tomomitsu
Tsukasaki, Kunihiro
Nagai, Hirokazu
Funding for this research was provided by:
National Cancer Center Research and Development Fund (23-A-16, 23-A-17, 26-A-4, 29-A-3, 2020-J-3, 2023-J-03)
Ministry of Health, Labour and Welfare (Grants-in-Aid for Cancer Research (20S-1, 20S-6, 23-A-16, 23-A-17), Health, Labour Sciences Research Grant for Clinical Cancer Research (19-20, 22-14))
Nagoya University
Article History
Received: 16 July 2023
Accepted: 8 January 2024
First Online: 27 January 2024
Declarations
:
: The study was done in accordance with the Declaration of Helsinki, the Ethical guideline for clinical research issued by the Ministry of Health, Labour and Welfare in Japan, and the Clinical Trials Act in Japan. The study protocol was approved by the Protocol Review Committee of Japan Clinical Oncology Group (JCOG) and the institutional review board of each participating center and the central review board of National Cancer Center (Tokyo, Japan), since enforcement of the Clinical Trials Act in Japan.
: Written informed consent was obtained from all patients before enrollment of the study.
: KS reported receiving grants and personal fees from Celgene, and Kyowa Kirin, grants from Otsuka, and personal fees from AstraZeneca, Eisai, Takeda, Janssen, Bristol Myers Squibb, Chugai, Nippon Shinyaku, Daiichi Sankyo, Meiji Seika, Ono, AbbVie, Novartis, Gilead, CSL Behling, Incyte, and Genmab outside the submitted work. KO reported receiving personal fees from Chugai, Kyowa Kirin, Meiji Seika, and Pfizer outside the submitted work. SO reported receiving personal fees from Novartis, Bristol Myers Squibb, Takeda, AstraZeneca, Janssen, and AbbVie outside the submitted work. NT reported receiving personal fees from Chugai and Kyowa Kirin outside the submitted work. TS reported receiving personal fees from Chugai, Novartis, Bristol Myers Squibb, Kyowa Kirin, and Taiho outside the submitted work. KM reported receiving grants and personal fees from Eisai, Nippon Shinyaku, Chugai, Asahi Kasei, and Sumitomo Dainippon, grants from Takeda, Otsuka, and Zenyaku, and personal fees from SymBio, Janssen, AstraZeneca, Bristol Myers Squibb, Meiji Seika, AbbVie, Novartis, and Incyte outside the submitted work. DM reported receiving grants and personal fees from AbbVie, Celgene, Kyowa Kirin, Chugai, Ono, Takeda, Janssen, Sanofi, Bristol Myers Squibb, Eisai, and MSD, grants from Amgen Astellas Biopharma, Novartis, Otsuka, Astellas, and Taiho, and personal fees from Nippon Shinyaku, Mundipharma, Zenyaku, SymBio, and AstraZeneca outside the submitted work. KA reported receiving grants from Chugai, Nippon Shinyaku, Takeda, Eisai, and Kyowa Kirin, and personal fees from Celgene, Otsuka, Novartis, and Astellas outside the submitted work. KT reported receiving grants from National Cancer Center and the Ministry of Health, Labour and Welfare during the conduct of the study, grants and personal fees from Meiji Seika, Daiichi Sankyo, and HUYABIO, grants from Kyowa Kirin, Bristol Myers Squibb, Bayer, and Regeneron, and personal fees from Ono, Solasia, Yakuruto, Eisai, and Takeda outside the submitted work. HN reported receiving grants and personal fees from AstraZeneca, Celgene, Mundipharma, Takeda, Chugai, Bristol Myers Squibb, Jansen, Kyowa Kirin, SymBio, Ono, and Eisai, grants from Zenyaku Kogyo, Bayer, AbbVie, MSD, and Nippon Shinyaku, and personal fees from Sanofi, Novartis, Chordia Therapeutics, Nihon Medi-Physics, and Meiji Seika outside the submitted work. All other authors have nothing to disclose.